The management of viral hepatitis in the setting of pregnancy requires special consideration. There are five liver-specific viruses (hepatitis A, B, C, D, E), each with unique epidemiology, tendency to chronicity, risk of liver complications and response to antiviral therapies. In the setting of pregnancy, the liver health of the mother, the influence of pregnancy on the clinical course of the viral infection and the effect of the virus or liver disease on the developing infant must be considered. Although all hepatitis viruses can harm the mother and the child, the greatest risk to maternal health and subsequently the fetus is seen with acute hepatitis A virus or hepatitis E virus infection during pregnancy. By contrast, the primary risks for hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus are related to the severity of the underlying liver disease in the mother and the risk of mother-to-child transmission (MTCT) for HBV and HCV. The prevention of MTCT is key to reducing the global burden of chronic viral hepatitis, and prevention strategies must take into consideration local health-care and socioeconomic challenges. This Review presents the epidemiology of acute and chronic viral hepatitis infection in pregnancy, the effect of pregnancy on the course of viral infection and, conversely, the influence of the viral infection on maternal and infant outcomes, including MTCT.
Acute hepatitis A virus (HAV) infection during pregnancy might increase the rates of adverse pregnancy outcomes; cases leading to fetal liver injury and mother-to-child transmission (MTCT) of HAV have been reported.
Pregnant women with chronic hepatitis B virus (HBV) infection might have an increased risk of preterm delivery and gestational diabetes.
There is risk of MTCT of HBV, especially in mothers with high levels of HBV DNA, but this risk is reduced with the use of maternal antiviral therapy and prompt administration of infant immunoprophylaxis.
Pregnant women with chronic hepatitis C virus (HCV) infection have increased rates of adverse pregnancy outcomes; MTCT occurs in 5% and is linked with invasive fetal monitoring and prolonged rupture of membranes.
Risks related to underlying cirrhosis can be more frequent in pregnant women with hepatitis D virus (HDV) infection; MTCT of HDV is rare and management is the same as HBV monoinfection.
Acute hepatitis E virus (HEV) infection in pregnancy is associated with an increased risk of maternal death and infant mortality, including higher rates of preterm delivery and stillbirths; MTCT of HEV can occur.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
World Health Organization. Global hepatitis report, 2017 (WHO, 2017).
Jacobsen, K. H. The global prevalence of hepatitis A virus infection and susceptibility: a systematic review (WHO, 2008).
Jacobsen, K. H. Globalization and the changing epidemiology of hepatitis a virus. Cold Spring Harb. Perspect. Med. 8, a031716 (2018).
Cho, G. J. et al. Hepatitis A virus infection during pregnancy in Korea: hepatitis A infection on pregnant women. Obstet. Gynecol. Sci. 56, 368–374 (2013).
Elinav, E. et al. Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor. Gastroenterology 130, 1129–1134 (2006).
Chaudhry, S. A. & Koren, G. Hepatitis A infection during pregnancy. Can. Fam. Physician 61, 963–964 (2015).
Simsek, Y. et al. Fulminant hepatitis A infection in second trimester of pregnancy requiring living-donor liver transplantation. J. Obstet. Gynaecol. Res. 38, 745–748 (2012).
Casey, L. C. et al. Acute liver failure (ALF) in pregnancy: how much is pregnancy-related? Hepatology https://doi.org/10.1002/hep.31144 (2020).
Leikin, E. et al. Intrauterine transmission of hepatitis A virus. Obstet. Gynecol. 88, 690–691 (1996).
Jiang, W. et al. Sofosbuvir inhibits hepatitis A virus replication in vitro assessed by a cell-based fluorescent reporter system. Antivir. Res. 154, 51–57 (2018).
Advisory Committee on Immunization Practices, Fiore, A. E., Wasley, A. & Bell, B. P. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 55, 1–23 (2006).
Moro, P. L. et al. Reports to the vaccine adverse event reporting system after hepatitis a and hepatitis AB vaccines in pregnant women. Am. J. Obstet. Gynecol. 210, 561.e1–561.e6 (2014).
Groom, H. C. et al. Uptake and safety of hepatitis A vaccination during pregnancy: a vaccine safety datalink study. Vaccine 37, 6648–6655 (2019).
Revill, P. A. et al. The evolution and clinical impact of hepatitis B virus genome diversity. Nat. Rev. Gastroenterol. Hepatol. 17, 618–634 (2020).
MacLachlan, J. H. & Cowie, B. C. Hepatitis B virus epidemiology. Cold Spring Harb. Perspect. Med. 5, a021410 (2015).
Edmunds, W. J. et al. The influence of age on the development of the hepatitis B carrier state. Proc. R. Soc. Lond. B 253, 197–201 (1993).
Beasley, R. P. et al. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial. Lancet 2, 388–393 (1981).
Hu, Y. C. et al. Seroprevalence of hepatitis B virus in Taiwan 30 years after the commencement of the national vaccination program. PeerJ 6, e4297 (2018).
Hofstraat, S. H. I. et al. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review. Epidemiol. Infect. 145, 2873–2885 (2017).
Su, W. J. et al. The impact of universal infant hepatitis B immunization on reducing the hepatitis B carrier rate in pregnant women. J. Infect. Dis. 220, 1118–1126 (2019).
Walker, T. Y. et al. Characteristics of pregnant women with hepatitis B virus infection in 5 US public health jurisdictions, 2008-2012. Public Health Rep. 131, 685–694 (2016).
Shepard, C. W. et al. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev. 28, 112–125 (2006).
US Department of Health and Human Services. Hepatitis B basic information. HHS.gov https://www.hhs.gov/hepatitis/learn-about-viral-hepatitis/hepatitis-b-basics/index.html (2019).
Goldstein, S. T. et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int. J. Epidemiol. 34, 1329–1339 (2005).
Torimiro, J. N. et al. Rates of HBV, HCV, HDV and HIV type 1 among pregnant women and HIV type 1 drug resistance-associated mutations in breastfeeding women on antiretroviral therapy. BMC Pregnancy Childbirth 18, 504 (2018).
Liu, J. et al. Maternal pre-pregnancy infection with hepatitis B virus and the risk of preterm birth: a population-based cohort study. Lancet Glob. Health 5, e624–e632 (2017).
Ma, X. et al. Chronic hepatitis B virus infection and preterm labor(birth) in pregnant women–an updated systematic review and meta-analysis. J. Med. Virol. 90, 93–100 (2018).
Tse, K. Y., Ho, L. F. & Lao, T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J. Hepatol. 43, 771–775 (2005).
Tan, J. et al. Hepatitis B surface antigen positivity during pregnancy and risk of gestational diabetes mellitus: a systematic review and meta-analysis. J. Viral Hepat. 25, 1372–1383 (2018).
Han, Y.-T. et al. Clinical features and outcome of acute hepatitis B in pregnancy. BMC Infect. Dis. 14, 368 (2014).
Kimmich, N. et al. Liver transplantation during pregnancy for acute liver failure due to HBV infection: a case report. Case Rep. Obstet. Gynecol. 2013, 356560 (2013).
Bzowej, N. H. et al. Total alanine aminotransferase (ALT) flares in pregnant North American women with chronic hepatitis B infection: results from a prospective observational study. Am. J. Gastroenterol. 114, 1283–1291 (2019).
Liu, J. et al. Kinetic changes of viremia and viral antigens of hepatitis B virus during and after pregnancy. Medicine 94, e2001 (2015).
Soderstrom, A., Norkrans, G. & Lindh, M. Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. Scand. J. Infect. Dis. 35, 814–819 (2003).
ter Borg, M. J. et al. Exacerbation of chronic hepatitis B infection after delivery. J. Viral Hepat. 15, 37–41 (2008).
Lin, H. H. et al. Postpartum subsidence of hepatitis B viral replication in HBeAg-positive carrier mothers. J. Med. Virol. 29, 1–6 (1989).
Joshi, S. S. et al. Peripartum cytokine flares in a multiethnic cohort of chronic hepatitis B carriers does not correlate with hepatitis B virus suppression or increased risk of liver disease. Am. J. Reprod. Immunol. 78, e12707 (2017).
Nguyen, V. et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Aliment. Pharmacol. Ther. 39, 1225–1234 (2014).
Kushner, T. et al. Incidence, determinants and outcomes of pregnancy-associated hepatitis B flares: a regional hospital-based cohort study. Liver Int. 38, 813–820 (2018).
Pan, C. Q. et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N. Engl. J. Med. 374, 2324–2334 (2016).
Greenup, A. J. et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J. Hepatol. 61, 502–507 (2014).
Jourdain, G. et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N. Engl. J. Med. 378, 911–923 (2018).
Terrault, N. A. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67, 1560–1599 (2018).
Giles, M. et al. Clinical and virological predictors of hepatic flares in pregnant women with chronic hepatitis B. Gut 64, 1810–1815 (2015).
Liu, J. et al. Baseline hepatitis B virus titer predicts initial postpartum hepatic flare: a multicenter prospective study. J. Clin. Gastroenterol. 52, 902–907 (2017).
Funk, A. et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(20)30586-7 (2020).
Brown, R. S. Jr et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology 63, 319–333 (2016).
Liu, J. et al. Presence of hepatitis B virus markers in umbilical cord blood: exposure to or infection with the virus? Dig. Liver Dis. 51, 864–869 (2019).
Mavilia, M. G. & Wu, G. Y. Mechanisms and prevention of vertical transmission in chronic viral hepatitis. J. Clin. Transl. Hepatol. 5, 119–129 (2017).
Ali, B. A. et al. Expression of hepatitis B virus genes in early embryonic cells originated from hamster ova and human spermatozoa transfected with the complete viral genome. Asian J. Androl. 8, 273–279 (2006).
Nie, R. et al. Presence of hepatitis B virus in oocytes and embryos: a risk of hepatitis B virus transmission during in vitro fertilization. Fertil. Steril. 95, 1667–1671 (2011).
Hu, X. L. et al. The presence and expression of the hepatitis B virus in human oocytes and embryos. Hum. Reprod. 26, 1860–1867 (2011).
WHO Publication. Hepatitis B vaccines: WHO position paper — recommendations. Vaccine 28, 589–590 (2010).
Centers for Disease Control and Prevention. Perinatal transmission. CDC https://www.cdc.gov/hepatitis/hbv/perinatalxmtn.htm (2020).
Amini, A. et al. Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis. BMC Infect. Dis. 17, 698 (2017).
Cheung, K. W. et al. Optimal timing of hepatitis B virus DNA quantification and clinical predictors for higher viral load during pregnancy. Acta Obstet. Gynecol. Scand. 98, 1301–1306 (2019).
Wen, W. H. et al. Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection. Hepatology 64, 1451–1461 (2016).
Samadi Kochaksaraei, G. et al. Cost-effectiveness of quantitative hepatitis B virus surface antigen testing in pregnancy in predicting vertical transmission risk. Liver Int. 36, 1604–1610 (2016).
Thilakanathan, C. et al. Mother-to-child transmission of hepatitis B: examining viral cut-offs, maternal HBsAg serology and infant testing. Liver Int. 38, 1212–1219 (2018).
Cheung, K. W. et al. The effect of rupture of membranes and labour on the risk of hepatitis B vertical transmission: prospective multicentre observational study. Eur. J. Obstet. Gynecol. Reprod. Biol. 232, 97–100 (2019).
Han, Z. et al. Mother-to-child transmission of hepatitis B virus after amniocentesis: a retrospective matched cohort study. Prenat. Diagn. 39, 431–440 (2019).
Yi, W. et al. Risk of vertical transmission of hepatitis B after amniocentesis in HBs antigen-positive mothers. J. Hepatol. 60, 523–529 (2014).
Xu, D. Z. et al. Role of placental tissues in the intrauterine transmission of hepatitis B virus. Am. J. Obstet. Gynecol. 185, 981–987 (2001).
Mackie, F. L. et al. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. BJOG 124, 32–46 (2017).
Yang, M. et al. Cesarean section to prevent mother-to-child transmission of hepatitis B virus in China: a meta-analysis. BMC Pregnancy Childbirth 17, 303 (2017).
Dunkelberg, J. C. et al. Hepatitis B and C in pregnancy: a review and recommendations for care. J. Perinatol. 34, 882–891 (2014).
Stevens, C. E. et al. HBeAg and anti-HBe detection by radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J. Med. Virol. 3, 237–241 (1979).
Zou, H. et al. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J. Viral Hepat. 19, e18–e25 (2012).
Wen, W. H. et al. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J. Hepatol. 59, 24–30 (2013).
Cheung, K. W. et al. Immunoprophylaxis failure of infants born to hepatitis B carrier mothers following routine vaccination. Clin. Gastroenterol. Hepatol. 16, 144–145 (2018).
Wiseman, E. et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med. J. Aust. 190, 489–492 (2009).
Benhammou, V. et al. HBV or HCV coinfection in HIV-1-infected pregnant women in France: prevalence and pregnancy outcomes. J. Acquir. Immune Defic. Syndr. 77, 439–450 (2018).
Mave, V. et al. Impact of maternal hepatitis B virus coinfection on mother-to-child transmission of HIV. HIV. Med. 15, 347–354 (2014).
Chotun, N. et al. Hepatitis B virus infection in HIV-exposed infants in the Western Cape, South Africa. Vaccine 33, 4618–4622 (2015).
Vanclaire, J., Cornu, C. & Sokal, E. M. Fulminant hepatitis B in an infant born to a hepatitis Be antibody positive, DNA negative carrier. Arch. Dis. Child. 66, 983–985 (1991).
Delaplane, D. et al. Fatal hepatitis B in early infancy: the importance of identifying HBsAg-positive pregnant women and providing immunoprophylaxis to their newborns. Pediatrics 72, 176–180 (1983).
Sacher, M., Unger, F. D. & Eder, G. Vertical hepatitis B transmission by anti-HBe positive hepatitis B carrier mothers. Padiatr. Padol. 21, 141–146 (1986).
Bahn, A. et al. Selection of a precore mutant after vertical transmission of different hepatitis B virus variants is correlated with fulminant hepatitis in infants. J. Med. Virol. 47, 336–341 (1995).
Schaefer, E., Koeppen, H. & Wirth, S. Low level virus replication in infants with vertically transmitted fulminant hepatitis and their anti-HBe positive mothers. Eur. J. Pediatr. 152, 581–584 (1993).
Chen, H. L. et al. Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination. Hepatology 39, 58–63 (2004).
Bigna, J. J. et al. Gender development and hepatitis B and C infections among pregnant women in Africa: a systematic review and meta-analysis. Infect. Dis. Poverty 8, 16 (2019).
Wang, Y. et al. Prevalence of chronic hepatitis B and status of HBV care among rural women who planned to conceive in China. Sci. Rep. 7, 12090 (2017).
Segeral, O. et al. Usefulness of a serial algorithm of HBsAg and HBeAg rapid diagnosis tests to detect pregnant women at risk of HBV mother-to-child transmission in Cambodia, the ANRS 12328 pilot study. J. Clin. Virol. 109, 29–34 (2018).
Cornberg, M. et al. The role of quantitative hepatitis B surface antigen revisited. J. Hepatol. 66, 398–411 (2017).
European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370–398 (2017).
Fujiko, M. et al. Chronic hepatitis B in pregnant women: is hepatitis B surface antigen quantification useful for viral load prediction? Int. J. Infect. Dis. 41, 83–89 (2015).
Sun, K. X. et al. A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women. Vaccine 30, 5335–5340 (2012).
Patel, N. H. et al. Analysis of serum hepatitis B virus RNA levels in a multiethnic cohort of pregnant chronic hepatitis B carriers. J. Clin. Virol. 111, 42–47 (2019).
Shimakawa, Y. et al. Hepatitis B core-related antigen (HBcrAg): an alternative to HBV DNA to assess treatment eligibility in Africa. Clin. Infect. Dis. 70, 1442–1452 (2019).
Wang, C. et al. Protective effect of an improved immunization practice of mother-to-infant transmission of hepatitis B virus and risk factors associated with immunoprophylaxis failure. Medicine 95, e4390 (2016).
Kang, W. et al. Risk factors associated with immunoprophylaxis failure against mother to child transmission of hepatitis B virus and hepatitis B vaccination status in Yunnan province, China. Vaccine 32, 3362–3366 (2014).
Isaacs, D. et al. Ethical issues in preventing mother-to-child transmission of hepatitis B by immunisation. Vaccine 29, 6159–6162 (2011).
Eke, A. C. et al. Hepatitis B immunoglobulin during pregnancy for prevention of mother-to-child transmission of hepatitis B virus. Cochrane Database Syst. Rev. 2, CD008545 (2017).
Childs, L., Roesel, S. & Tohme, R. A. Status and progress of hepatitis B control through vaccination in the South-East Asia region, 1992-2015. Vaccine 36, 6–14 (2018).
Breakwell, L. et al. The status of hepatitis B control in the African region. Pan Afr. Med. J. 27, 17 (2017).
Wiesen, E., Diorditsa, S. & Li, X. Progress towards hepatitis B prevention through vaccination in the Western Pacific, 1990–2014. Vaccine 34, 2855–2862 (2016).
Cui, F. et al. Evaluation of policies and practices to prevent mother to child transmission of hepatitis B virus in China: results from China GAVI project final evaluation. Vaccine 31, J36–J42 (2013).
Xeuatvongsa, A. et al. Improving hepatitis B birth dose in rural Lao People’s Democratic Republic through the use of mobile phones to facilitate communication. Vaccine 34, 5777–5784 (2016).
World Health Organization. A systematic review of monovalent hepatitis B vaccine thermostability (WHO, 2016).
Wait, S. et al. Hepatitis B and hepatitis C in southeast and southern Asia: challenges for governments. Lancet Gastroenterol. Hepatol. 1, 248–255 (2016).
Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry interim report for 1 January 1989 through 31 January 2020 (Registry Coordinating Center, 2020).
Ayres, A. et al. Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations. J. Viral Hepat. 21, 809–817 (2014).
Hu, Y. H. et al. Tenofovir rescue therapy in pregnant females with chronic hepatitis B. World J. Gastroenterol. 21, 2504–2509 (2015).
World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection (WHO, 2015).
Shyamala, V. et al. Assessment of the target-capture PCR hepatitis B virus (HBV) DNA quantitative assay and comparison with commercial HBV DNA quantitative assays. J. Clin. Microbiol. 42, 5199–5204 (2004).
Han, G. R. et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J. Hepatol. 55, 1215–1221 (2011).
Sarin, S. K. et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol. Int. 10, 1–98 (2016).
Shi, Z. et al. Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review. Arch. Pediatr. Adolesc. Med. 165, 837–846 (2011).
Zheng, Y. et al. Should chronic hepatitis B mothers breastfeed? A meta analysis. BMC Public Health 11, 502 (2011).
World Health Organization. Hepatitis B and breastfeeding (WHO, 1996).
Hu, X., Wang, L. & Xu, F. Guides concerning tenofovir exposure via breastfeeding: a comparison of drug dosages by developmental stage. Int. J. Infect. Dis. 87, 8–12 (2019).
Benaboud, S. et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d’Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob. Agents Chemother. 55, 1315–1317 (2011).
Grant, P. M. & Cotter, A. G. Tenofovir and bone health. Curr. Opin. HIV AIDS 11, 326–332 (2016).
Schillie, S. et al. Update: Shortened interval for postvaccination serologic testing of infants born to hepatitis B-infected mothers. Morb. Mortal. Wkly. Rep. 64, 1118–1120 (2015).
Indolfi, G. et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol. Hepatol. 4, 466–476 (2019).
Woodring, J. et al. Integrating HIV, hepatitis B and syphilis screening and treatment through the Maternal, Newborn and Child Health platform to reach global elimination targets. West. Pac. Surveill. Response J. 8, 1–5 (2017).
Gavi. Gavi Alliance Programme and Policy Committee meeting 23–24 October 2019 (Gavi, 2019).
World Health Organization. Guidelines on hepatitis B and C testing (WHO, 2016).
Jing, W. et al. Cost-effectiveness of couple-based immunization strategy to prevent mother-to-child transmission of hepatitis B virus in China: a decision-analytic Markov model. EClinicalMedicine 19, 100264 (2020).
Rajbhandari, R. et al. Discontinuity of care for mothers with chronic hepatitis B diagnosed during pregnancy. J. Viral Hepat. 23, 561–568 (2016).
Cheung, K. W. et al. Pattern and predictors of medical care received by hepatitis B carriers during pregnancy and after delivery. Public Health 168, 36–42 (2019).
Davis, C. et al. Highly diverse hepatitis C strains detected in sub-Saharan Africa have unknown susceptibility to direct-acting antiviral treatments. Hepatology 69, 1426–1441 (2019).
Bialek, S. R. & Terrault, N. A. The changing epidemiology and natural history of hepatitis C virus infection. Clin. Liver Dis. 10, 697–715 (2006).
Wei, L. & Huang, Y. H. Long-term outcomes in patients with chronic hepatitis C in the current era of direct-acting antiviral agents. Expert Rev. Anti Infect. Ther. 17, 311–325 (2019).
Petruzziello, A. et al. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J. Gastroenterol. 22, 7824–7840 (2016).
DeMaria, A. Jr Hearing from the silent epidemic. Ann. Intern. Med. 166, 846–847 (2017).
Gower, E. et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol. 61, S45–S57 (2014).
Onofrey, S. et al. Hepatitis C virus infection among adolescents and young adults: Massachusetts, 2002-2009. Morb. Mortal. Wkly. Rep. 60, 537–541 (2011).
Ly, K. N. et al. Hepatitis C virus infection among reproductive-aged women and children in the United States, 2006 to 2014. Ann. Intern. Med. 166, 775–782 (2017).
American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C (AASLD/IDSA, 2020).
Chaillon, A. et al. Cost-effectiveness of universal hepatitis C virus screening of pregnant women in the United States. Clin. Infect. Dis. 69, 1888–1895 (2019).
US Preventive Services Task Force et al. Screening for hepatitis C virus infection in adolescents and adults: US preventive services task force recommendation statement. JAMA 323, 970–975 (2020).
Waruingi, W. et al. Hepatitis C virus universal screening versus risk based selective screening during pregnancy. J. Neonatal Perinat. Med. 8, 371–378 (2015).
El-Kamary, S. S. et al. Reliability of risk-based screening for hepatitis C virus infection among pregnant women in Egypt. J. Infect. 70, 512–519 (2015).
Chibber, R., El-Saleh, E. & El Harmi, J. Female circumcision: obstetrical and psychological sequelae continues unabated in the 21st century. J. Matern. Fetal Neonatal Med. 24, 833–836 (2011).
Society for Maternal-Fetal Medicine, Hughes, B. L., Page, C. M. & Kuller, J. A. Hepatitis C in pregnancy: screening, treatment, and management. Am. J. Obstet. Gynecol. 217, B2–B12 (2017).
Kaberg, M. & Weiland, O. Hepatitis C elimination - macro-elimination. Liver Int. 40, 61–66 (2020).
Yu, M. L. et al. 2020 Taiwan consensus statement on the management of hepatitis C: part (II) special populations. J. Formos. Med. Assoc. 119, 1135–1157 (2020).
Yang, L. et al. Effect of hepatitis C virus infection on the outcomes of in vitro fertilization. Int. J. Clin. Exp. Med. 8, 6230–6235 (2015).
Post, J. J. Update on hepatitis C and implications for pregnancy. Obstet. Med. 10, 157–160 (2017).
Shaw-Jackson, C. et al. In vitro fertilization for women infected by hepatitis C virus: a matched case-control study and a systematic literature review. J. Assist. Reprod. Genet. 34, 587–597 (2017).
Money, D. et al. Obstetrical and neonatal outcomes among women infected with hepatitis C and their infants. J. Obstet. Gynaecol. Can. 36, 785–794 (2014).
Huang, Q. T. et al. Chronic hepatitis C virus infection is associated with increased risk of preterm birth: a meta-analysis of observational studies. J. Viral Hepat. 22, 1033–1042 (2015).
Rezk, M. & Omar, Z. Deleterious impact of maternal hepatitis-C viral infection on maternal and fetal outcome: a 5-year prospective study. Arch. Gynecol. Obstet. 296, 1097–1102 (2017).
Belay, T. et al. Intrahepatic cholestasis of pregnancy with concomitant hepatitis C virus infection, Joan C. Edwards SOM, Marshall University. Eur. J. Gastroenterol. Hepatol. 27, 372–374 (2015).
Wijarnpreecha, K. et al. Hepatitis C infection and intrahepatic cholestasis of pregnancy: a systematic review and meta-analysis. Clin. Res. Hepatol. Gastroenterol. 41, 39–45 (2017).
Kushner, T. & Terrault, N. A. Hepatitis C in pregnancy: a unique opportunity to improve the hepatitis C cascade of care. Hepatol. Commun. 3, 20–28 (2019).
Conte, D. et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 31, 751–755 (2000).
Benova, L. et al. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin. Infect. Dis. 59, 765–773 (2014).
Mok, J. et al. When does mother to child transmission of hepatitis C virus occur? Arch. Dis. Child. Fetal Neonatal Ed. 90, F156–F160 (2005).
Cottrell, E. B. et al. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. Preventive Services Task Force. Ann. Intern. Med. 158, 109–113 (2013).
Freriksen, J. J. M. et al. Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation – implications for maternal dosing, foetal exposure, and safety for mother and child. Aliment. Pharmacol. Ther. 50, 738–750 (2019).
Chappell C. A. et al. A phase 1 study of ledipasvir/sofosbuvir in pregnant women with hepatitis C virus [abstract 87]. Presented at the Conference on Retroviruses and Opportunistic Infections (2019).
El-Sayed, M. et al. THU-137-DAA therapy in women of child bearing age: accidental conception during therapy and pregnancy outcome [abstract]. J. Hepatol. 70, e221 (2019).
El-Sayed, M. H.& Indolfi, G. Hepatitis C virus treatment in children: a challenge for hepatitis C virus elimination. Semin. Liver Dis. 40, 213–224 (2020).
Indolfi, G. et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol. Hepatol. 4, 477–487 (2019).
Dahl, E. H. et al. Leaving no one behind: towards equitable global elimination of hepatitis C. J. Glob. Health 10, 010308 (2020).
Kushner, T. et al. Evaluating women’s preferences for hepatitis C treatment during pregnancy. Hepatol. Commun. 2, 1306–1310 (2018).
Gagnon, A. et al. Prenatal invasive procedures in women with hepatitis B, hepatitis C, and/or human immunodeficiency virus infections. J. Obstet. Gynaecol. Can. 36, 648–653 (2014).
Garcia-Tejedor, A. et al. Risk factors for vertical transmission of hepatitis C virus: a single center experience with 710 HCV-infected mothers. Eur. J. Obstet. Gynecol. Reprod. Biol. 194, 173–177 (2015).
Mast, E. E. et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J. Infect. Dis. 192, 1880–1889 (2005).
Polywka, S. et al. Low risk of vertical transmission of hepatitis C virus by breast milk. Clin. Infect. Dis. 29, 1327–1329 (1999).
Zimmermann, R. et al. Hepatitis C virus in breast milk. Lancet 345, 928 (1995).
European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. BJOG 108, 371–377 (2001).
Pfaender, S. et al. Inactivation of hepatitis C virus infectivity by human breast milk. J. Infect. Dis. 208, 1943–1952 (2013).
Hillemanns, P. et al. Obstetric risks and vertical transmission of hepatitis C virus infection in pregnancy. Acta Obstet. Gynecol. Scand. 79, 543–547 (2000).
Bal, A. & Petrova, A. Single clinical practice’s report of testing initiation, antibody clearance, and transmission of hepatitis C virus (HCV) in infants of chronically HCV-infected mothers. Open Forum Infect. Dis. 3, ofw021 (2016).
Polywka, S. et al. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J. Med. Virol. 78, 305–310 (2006).
Mack, C. L. et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J. Pediatric Gastroenterol. Nutr. 54, 838–855 (2012).
Gross, M. S., Ruth, A. R. & Rasmussen, S. A. Respect women, promote health and reduce stigma: ethical arguments for universal hepatitis C screening in pregnancy. J. Med. Ethics 46, 674–677 (2020).
US Preventive Services Task Force. Screening for hepatitis B virus infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. JAMA 322, 349–354 (2019).
Chappell, C. A. et al. Hepatitis C virus screening among children exposed during pregnancy. Pediatrics 141, e20173273 (2018).
Kuncio, D. E. et al. Failure to test and identify perinatally infected children born to hepatitis C virus-infected women. Clin. Infect. Dis. 62, 980–985 (2016).
Alvarado-Mora, M. V. et al. An update on HDV: virology, pathogenesis and treatment. Antivir. Ther. 18, 541–548 (2013).
Stockdale, A. J. et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J. Hepatol. 73, 523–532 (2020).
Chen, H. Y. et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut 66, 381–382 (2018).
Mansour, W. et al. Prevalence, risk factors, and molecular epidemiology of hepatitis B and hepatitis delta virus in pregnant women and in patients in Mauritania. J. Med. Virol. 84, 1186–1198 (2012).
Aftab, M. et al. Characterization of hepatitis delta virus among pregnant women of Pakistan. Viral Immunol. 32, 335–340 (2019).
Chen, X. et al. A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians. Hepatology 66, 1739–1749 (2017).
Hughes, S. A., Wedemeyer, H. & Harrison, P. M. Hepatitis delta virus. Lancet 378, 73–85 (2011).
Hagstrom, H. et al. Outcomes of pregnancy in mothers with cirrhosis: a national population-based cohort study of 1.3 million pregnancies. Hepatol. Commun. 2, 1299–1305 (2018).
Sellier, P. O. et al. Hepatitis B virus-hepatitis D virus mother-to-child co-transmission: a retrospective study in a developed country. Liver Int. 38, 611–618 (2018).
Dusheiko, G. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int. 33, 137–150 (2013).
Aggarwal, R. Diagnosis of hepatitis E. Nat. Rev. Gastroenterol. Hepatol. 10, 24–33 (2013).
Li, R. C. et al. Seroprevalence of hepatitis E virus infection, rural southern People’s Republic of China. Emerg. Infect. Dis. 12, 1682–1688 (2006).
Khuroo, M. S., Khuroo, M. S. & Khuroo, N. S. Transmission of hepatitis E virus in developing countries. Viruses 8, 253 (2016).
Debing, Y. et al. Update on hepatitis E virology: implications for clinical practice. J. Hepatol. 65, 200–212 (2016).
Dagnew, M. et al. Hepatitis E virus infection among pregnant women in Africa: systematic review and meta-analysis. BMC Infect. Dis. 19, 519 (2019).
Bisayher, S. et al. Seroprevalence and risk factors of hepatitis E among women of childbearing age in the Xieng Khouang province (Lao People’s Democratic Republic), a cross-sectional survey. J. Viral Hepat. 113, 298–304 (2019).
Li, P. et al. The global epidemiology of hepatitis E virus infection: a systematic review and meta-analysis. Liver Int. 40, 1516–1528 (2020).
Aggarwal, R. Hepatitis E: clinical presentation in disease-endemic areas and diagnosis. Semin. Liver Dis. 33, 30–40. (2013).
Berglov, A., Hallager, S. & Weis, N. Hepatitis E during pregnancy: maternal and foetal case-fatality rates and adverse outcomes–a systematic review. J. Viral Hepat. 26, 1240–1248 (2019).
Khuroo, M. S. & Kamili, S. Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy. J. Viral Hepat. 10, 61–69 (2003).
Zhuang, H., Cao, X. Y., Liu, C. B. & Wang, G. M. Epidemiology of hepatitis E in China. Gastroenterol. Jpn. 26 (Suppl. 3), 135–138 (1991).
Li, M. et al. Hepatitis E virus infection and its associated adverse feto-maternal outcomes among pregnant women in Qinhuangdao, China. J. Matern. Fetal Neonatal. Med. 33, 3647–3651 (2020).
El Sayed Zaki, M., El Razek, M. M. A. & El Razek, H. M. A. Maternal-fetal hepatitis E transmission: is it underestimated? J. Clin. Transl. Hepatol. 2, 117–123 (2014).
Kamar, N. et al. Hepatitis E virus infection. Clin. Microbiol. Rev. 27, 116–138 (2014).
Gouilly, J. et al. Genotype specific pathogenicity of hepatitis E virus at the human maternal-fetal interface. Nat. Commun. 9, 4748 (2018).
Knegendorf, L. et al. Hepatitis E virus replication and interferon responses in human placental cells. Hepatol. Commun. 2, 173–187 (2018).
Gad, Y. Z. et al. Seroprevalence of subclinical HEV infection in asymptomatic, apparently healthy, pregnant women in Dakahlya Governorate, Egypt. Asian J. Transfus. Sci. 5, 136–139 (2011).
Yang, C. et al. Increased oestradiol in hepatitis E virus-infected pregnant women promotes viral replication. J. Viral Hepat. 25, 742–751 (2018).
Kumar, A. et al. Impact of maternal nutrition in hepatitis E infection in pregnancy. Arch. Gynecol. Obstet. 296, 885–895 (2017).
Rein, D. B. et al. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology 55, 988–997 (2012).
Gurley, E. S. et al. Estimating the burden of maternal and neonatal deaths associated with jaundice in Bangladesh: possible role of hepatitis E infection. Am. J. Public Health 102, 2248–2254 (2012).
Sharma, S. et al. Risk factors for vertical transmission of hepatitis E virus infection. J. Viral Hepat. 24, 1067–1075 (2017).
Nishiyama, T. et al. Screening of novel drugs for inhibiting hepatitis E virus replication. J. Virol. Methods 270, 1–11 (2019).
Bertuzzo, V. R. et al. Pregnant woman saved with liver transplantation from acute liver failure due to hepatitis E virus. Transpl. Int. 27, e87–e89 (2014).
Li, S. W. et al. The development of a recombinant hepatitis E vaccine HEV 239. Hum. Vaccin. Immunother. 11, 908–914 (2015).
Cao, Y. et al. Development of new hepatitis E vaccines. Hum. Vaccin. Immunother. 14, 2254–2262 (2018).
Zaman, K. et al. HEV study protocol: design of a cluster-randomised, blinded trial to assess the safety, immunogenicity and effectiveness of the hepatitis E vaccine HEV 239 (Hecolin) in women of childbearing age in rural Bangladesh. BMJ Open 10, e033702 (2020).
Zhao, Y. et al. A preliminary cost-effectiveness analysis of hepatitis E vaccination among pregnant women in epidemic regions. Hum. Vaccin. Immunother. 12, 2003–2009 (2016).
N.A.T. has received institutional grant support unrelated to this work from Gilead Sciences and Roche/Genentech. M.T.L. is an adviser or has received research grants from AbbVie, Gilead Sciences, Merck/MSD and Bayer. G.J. owns equities in Sanofi and has received grants from Gilead. K.W.C. has no competing interests.
Peer review information
Nature Reviews Gastroenterology & Hepatology thanks T. Chen and the other, anonymous, reviewers for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Gavi, The Vaccine Alliance: https://www.gavi.org/
About this article
Cite this article
Terrault, N.A., Levy, M.T., Cheung, K.W. et al. Viral hepatitis and pregnancy. Nat Rev Gastroenterol Hepatol 18, 117–130 (2021). https://doi.org/10.1038/s41575-020-00361-w
Nature Reviews Gastroenterology & Hepatology (2021)
Nature Reviews Gastroenterology & Hepatology (2021)